Literature DB >> 21893119

Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis.

Rei Kawashima1, Yuki I Kawamura, Tomoyuki Oshio, Aoi Son, Motomi Yamazaki, Teruki Hagiwara, Toshihiko Okada, Kyoko Inagaki-Ohara, Ping Wu, Suzanne Szak, Yutaka J Kawamura, Fumio Konishi, Oki Miyake, Hideaki Yano, Yukio Saito, Linda C Burkly, Taeko Dohi.   

Abstract

BACKGROUND & AIMS: TWEAK, a member of the tumor necrosis factor (TNF) superfamily, promotes intestinal epithelial cell injury and signals through the receptor Fn14 following irradiation-induced tissue damage and during development of colitis in mice. Interleukin (IL)-13, an effector of tissue damage in similar models, has been associated with the pathogenesis of ulcerative colitis (UC). We investigated interactions between TWEAK and IL-13 following mucosal damage in mice.
METHODS: We compared patterns of gene expression in intestinal tissues from wild-type and TWEAK knockout mice following γ-irradiation. Intestinal explants from these mice were used to detect cell damage induced by IL-13 and TNF-α. Levels of messenger RNA for IL-13, TWEAK, and Fn14 were measured in mucosal samples from patients with UC.
RESULTS: Based on gene expression analysis, TWEAK mediates γ-irradiation-induced epithelial cell cycle arrest and apoptosis. However, TWEAK alone did not induce damage or apoptosis of primary intestinal epithelial cells. On the other hand, exogenous IL-13 activated caspase-3 in naïve intestinal explants; this process required TWEAK, Fn14, and secretion of endogenous TNF-α which was mediated by ADAM17. Conversely, activation of caspase by exogenous TNF-α required IL-13, TWEAK, and Fn14. In mucosa from patients with UC, messenger RNA levels of IL-13, TWEAK, and Fn14 increased with level of disease severity.
CONCLUSIONS: IL-13-induced damage of intestinal epithelial cells requires TWEAK, its receptor (Fn14), and TNF-α. IL-13, TNF-α, TWEAK, and Fn14 could perpetuate and aggravate intestinal inflammation in patients with UC.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893119     DOI: 10.1053/j.gastro.2011.08.040

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients.

Authors:  Jin-Shan Feng; Zheng Yang; Yu-Zhen Zhu; Zhou Liu; Can-Can Guo; Xue-Bao Zheng
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 4.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

5.  Protective Role for TWEAK/Fn14 in Regulating Acute Intestinal Inflammation and Colitis-Associated Tumorigenesis.

Authors:  Luca Di Martino; Maneesh Dave; Paola Menghini; Wei Xin; Kristen O Arseneau; Theresa T Pizarro; Fabio Cominelli
Journal:  Cancer Res       Date:  2016-09-09       Impact factor: 12.701

Review 6.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

Review 7.  MK2 puts an additional brake on RIPK1 cytotoxic potential.

Authors:  Yves Dondelinger; Tom Delanghe; Mathieu M J Bertrand
Journal:  Cell Death Differ       Date:  2018-01-09       Impact factor: 15.828

8.  Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors:  Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

Review 9.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 10.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.